Kane Biotech Ownership
| KNBIF Stock | USD 0.03 0 4.11% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Kane |
Kane Pink Sheet Ownership Analysis
About 27.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.03. Kane Biotech last dividend was issued on the 13th of March 2017. The entity had 1:5 split on the 13th of March 2017. Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada. Kane Biotech is traded on OTC Exchange in the United States.The quote for Kane Biotech is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Kane Biotech contact Mark AhrensTownsend at 204 453 1301 or learn more at https://kanebiotech.com.Currently Active Assets on Macroaxis
Other Information on Investing in Kane Pink Sheet
Kane Biotech financial ratios help investors to determine whether Kane Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kane with respect to the benefits of owning Kane Biotech security.